Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Bouattour, M.; Cheng, A. L.; Dayyani, F.; Khalil, D.; Li, D.; Liao, C. Y.; LoĢpez, C. L.; Rimassa, L.; Deutsch, J.; Pailden, J.; Patel, M.; Ng, J.; Henkel, A.; Ferlini, C. |
| Abstract Title: | Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406185 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS4190 |
| Notes: | Meeting Abstract: TPS4190 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
